Harnessing the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process.
RNAi is a Nobel-prize winning discovery that enables repression of disease-causing genes, using small interfering RNA molecules (siRNA). These molecules are by nature digital, discrete, and highly specific to an active site. Their chemical topology naturally lends itself to combinatorial searches and AI algorithms, which become particularly powerful and predictive when combined with cost-effective DNA synthesis and sequencing technologies.
Our platform leverages massively-parallel processes to map the chemical space and reveal the structure-activity relationship (SAR) of RNAi molecules. Employing big data, we optimize every component of siRNA molecules, including their safety, efficiency, and duration of effect.
While there are many broad applications for our platform, we are currently focused on developing the next generation of RNAi therapeutics to silence the disease-causing genes that are responsible for respiratory illnesses. In this process, we take a principled human genetics approach to our target selection, enabling our fully-programmable RNAi molecules to precisely eliminate the root causes of such diseases.
We appreciate the interest that our valued partners and funders have found in our technologies.